Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients

Fig. 4

Safety evaluation of cisplatin combined with IL-2 versus cisplatin alone by thoracic injection for controlling MPE. a The therapy of cisplatin combined with IL-2 displayed the same incidence rate of myelotoxicity compared with cisplatin alone (p > 0.05). b The therapy of cisplatin combined with IL-2 had the same incidence of nausea/vomiting compared with cisplatin alone (p > 0.05); OR, odds ratio

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us